In fact, the ASC treatment showed50% of decreased in the C5ar1 levels when compared with the control group (0.5vs. 0.95, respectively, p=0.02) and with the MG group (0.5vs. 0.81, respectively, p= 0.05). The gene discussed is C5AR1; the disease is myasthenia gravis.